UNSPSC 51332809: Clospirazine or spiclomazine

This classification denotes an antipsychotic agent with the molecular formula C22H24ClN3OS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G2V8248111, chemically known as 8-(3-(2-chloro-10-phenothiazinyl)propyl)-1-thia-4,8-diazaspiro(4,5)decan-3-one but generally known as clospirazine, which bears US NIH Compound Identifier 65714. European Medicines Agency schedules Spiclomazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10616MIG.

The term SPICLOMAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25, No. 10 1971, List 11). Clospirazine or spiclomazine bears US NLM identifiers UMLS ID C1883076 and NCI Concept Code C66557. SMILES: C1CN(CCC12NC(=O)CS2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)CL.

UNSPSC 51332809 Clospirazine or spiclomazine is a Commodity code with minimal recent activity aligned to its nominal scope. The three most recent state and local contract opportunities tagged under this code involve naloxone procurement, therapeutic pharmacy initiatives, and generic pharmaceutical supply agreements—none of which are clospirazine or spiclomazine products. The code appears to describe a specific pharmaceutical active ingredient with limited demand in state and local procurement, or opportunities are being miscoded by issuing bodies.

The recent opportunities show that state and local governments do actively procure pharmaceutical products, naloxone emergency response supplies, and multi-source generic medications through RFPs and IFBs. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026, response deadline. Activity under this code spans Florida, Texas, and Minnesota, with MMCAP offerings extending to Oregon. No recent opportunities explicitly solicit clospirazine or spiclomazine products; the code tag appears to be a data-quality issue rather than an active procurement category for this specific ingredient.